Low-dose heparin thromboembolism prophylaxis

John T Owings, F. William Blaisdell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To determine a rational approach to heparin dosing for thromboembolism prophylaxis. Design: Literature review. Results: Three commonly used heparin dosing regimens were identified: (1) standard low-dose heparin (5000 U administered subcutaneously 2-3 times per day); (2) adjusted- dose heparin (adequate to elevate the activated partial thromboplastin time to 5 seconds above the upper limit of normal); and (3) low-molecular-weight heparin (30 mg subcutaneously twice daily without monitoring). Conclusions: Adjusted-dose heparin thromboembolism prophylaxis is both the safest and most reliable method currently available.

Original languageEnglish (US)
Pages (from-to)1069-1073
Number of pages5
JournalArchives of Surgery
Volume131
Issue number10
StatePublished - Oct 1996

Fingerprint

Thromboembolism
Heparin
Partial Thromboplastin Time
Low Molecular Weight Heparin

ASJC Scopus subject areas

  • Surgery

Cite this

Owings, J. T., & Blaisdell, F. W. (1996). Low-dose heparin thromboembolism prophylaxis. Archives of Surgery, 131(10), 1069-1073.

Low-dose heparin thromboembolism prophylaxis. / Owings, John T; Blaisdell, F. William.

In: Archives of Surgery, Vol. 131, No. 10, 10.1996, p. 1069-1073.

Research output: Contribution to journalArticle

Owings, JT & Blaisdell, FW 1996, 'Low-dose heparin thromboembolism prophylaxis', Archives of Surgery, vol. 131, no. 10, pp. 1069-1073.
Owings, John T ; Blaisdell, F. William. / Low-dose heparin thromboembolism prophylaxis. In: Archives of Surgery. 1996 ; Vol. 131, No. 10. pp. 1069-1073.
@article{8ca9dd268806470992998592977a04b4,
title = "Low-dose heparin thromboembolism prophylaxis",
abstract = "Objective: To determine a rational approach to heparin dosing for thromboembolism prophylaxis. Design: Literature review. Results: Three commonly used heparin dosing regimens were identified: (1) standard low-dose heparin (5000 U administered subcutaneously 2-3 times per day); (2) adjusted- dose heparin (adequate to elevate the activated partial thromboplastin time to 5 seconds above the upper limit of normal); and (3) low-molecular-weight heparin (30 mg subcutaneously twice daily without monitoring). Conclusions: Adjusted-dose heparin thromboembolism prophylaxis is both the safest and most reliable method currently available.",
author = "Owings, {John T} and Blaisdell, {F. William}",
year = "1996",
month = "10",
language = "English (US)",
volume = "131",
pages = "1069--1073",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Low-dose heparin thromboembolism prophylaxis

AU - Owings, John T

AU - Blaisdell, F. William

PY - 1996/10

Y1 - 1996/10

N2 - Objective: To determine a rational approach to heparin dosing for thromboembolism prophylaxis. Design: Literature review. Results: Three commonly used heparin dosing regimens were identified: (1) standard low-dose heparin (5000 U administered subcutaneously 2-3 times per day); (2) adjusted- dose heparin (adequate to elevate the activated partial thromboplastin time to 5 seconds above the upper limit of normal); and (3) low-molecular-weight heparin (30 mg subcutaneously twice daily without monitoring). Conclusions: Adjusted-dose heparin thromboembolism prophylaxis is both the safest and most reliable method currently available.

AB - Objective: To determine a rational approach to heparin dosing for thromboembolism prophylaxis. Design: Literature review. Results: Three commonly used heparin dosing regimens were identified: (1) standard low-dose heparin (5000 U administered subcutaneously 2-3 times per day); (2) adjusted- dose heparin (adequate to elevate the activated partial thromboplastin time to 5 seconds above the upper limit of normal); and (3) low-molecular-weight heparin (30 mg subcutaneously twice daily without monitoring). Conclusions: Adjusted-dose heparin thromboembolism prophylaxis is both the safest and most reliable method currently available.

UR - http://www.scopus.com/inward/record.url?scp=0029818743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029818743&partnerID=8YFLogxK

M3 - Article

C2 - 8857904

AN - SCOPUS:0029818743

VL - 131

SP - 1069

EP - 1073

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 10

ER -